CASI Pharmaceuticals (CASIF) Common Equity (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Common Equity came in at -$37.3 million in Q4 2025, down 2114.15% YoY from $1.9 million in Q4 2024, and down 30.39% on a QoQ basis from -$28.6 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Common Equity (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Common Equity data on file, last reported at -$37.3 million in Q4 2025.
- Quarterly Common Equity fell 2114.15% year-over-year to -$37.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$37.3 million (down 2114.15% YoY) and the FY2025 annual result came in at -$37.3 million, down 2114.15% from the prior year.
- Common Equity declined to -$37.3 million in Q4 2025, from -$28.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $32.2 billion in Q2 2023 to a low of -$8.1 billion in Q1 2025.
- A 5-year average of $5.2 billion and a median of $15.5 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity jumped 54113.22% — and 2025, when it plunged 52275.6%.
- Tracing CASIF's Common Equity over 5 years: stood at $84.5 million in 2021, then slumped by 47.25% to $44.6 million in 2022, then jumped by 54113.22% to $24.2 billion in 2023, then sank by 99.99% to $1.9 million in 2024, then slumped by 2114.15% to -$37.3 million in 2025.
- The last three Common Equity figures came in at -$37.3 million (Q4 2025), -$28.6 million (Q3 2025), and -$20.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | -58.27 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -37.28 Mn |
| Sep 30, 2025 | -28.59 Mn |
| Jun 30, 2025 | -20.31 Mn |
| Mar 31, 2025 | -8.07 Bn |
| Dec 31, 2024 | 1.85 Mn |
| Jun 30, 2024 | 9.02 Bn |
| Mar 31, 2024 | 15.47 Mn |
| Dec 31, 2023 | 24.17 Bn |
| Jun 30, 2023 | 32.23 Bn |
| Dec 31, 2022 | 44.57 Mn |
| Dec 31, 2021 | 84.50 Mn |